Journal of Clinical Endocrinology & Metabolism, Vol 78, 329-336, Copyright © 1994 by Endocrine Society

ARTICLES

Effect of a new oral somatostatin analog (SDZ CO 611) on gastric emptying, mouth to cecum transit time, and pancreatic and gut hormone release in normal male subjects

C Nelson-Piercy, PJ Hammond, ME Gwilliam, N Khandan-Nia, MJ Myers, MA Ghatei and SR Bloom
Department of Diagnostic Physics, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Sixteen healthy male volunteers participated in a randomized, double blind, parallel groups study. Subjects received either 1 or 5 mg SDZ CO 611 (a new, orally active somatostatin analog) twice daily over a 14- day period and acted as their own controls. Gastric emptying of 99mTc and mouth to cecum transit time, as measured by the breath hydrogen technique, after a mixed meal containing lactulose and 99mTc- diethylenetriaminepentaacetate, were assessed once before, twice during, and once after the period of study medication. Gastric emptying of 99mTc was significantly accelerated by the higher dose of SDZ CO 611, whereas mouth to cecum transit time was prolonged by the drug in a dose-dependent manner. Both doses of SDZ CO 611 led to suppression of the fasting level and postprandial release of several gastrointestinal and pancreatic hormones. This effect was more marked in those subjects taking 10 mg/day of the study medication. Motilin and pancreatic polypeptide were the most sensitive to the inhibitory actions of the analog. Glucose tolerance was significantly impaired by the 10-mg dose of the drug. We conclude that this new, orally active derivative of somatostatin is as effective on the gastrointestinal tract as the sc somatostatin analog octreotide. It would, therefore, be a useful advance in the treatment of gastroenteropancreatic tumors.

This article has been cited by other articles:

				A Foxx-Orenstein, M Camilleri, D Stephens, and D Burton Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans Gut, November 1, 2003; 52(11): 1555 - 1561. [Abstract] [Full Text] [PDF]

				C.M.B. Edwards, M.A. Cohen, and S.R. Bloom Peptides as drugs QJM, January 1, 1999; 92(1): 1 - 4. [Full Text] [PDF]

				S B Saslow, J S Scolapio, M Camilleri, L A Forstrom, G M Thomforde, D D Burton, J Rubin, H C Pitot, and A R Zinsmeister Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhoea Gut, May 1, 1998; 42(5): 628 - 634. [Abstract] [Full Text] [PDF]

				M I van Berge Henegouwen, T. M van Gulik, L M A Akkermans, J B M J Jansen, and D J Gouma The effect of octreotide on gastric emptying at a dosage used to prevent complications after pancreatic surgery: a randomised, placebo controlled study in volunteers Gut, December 1, 1997; 41(6): 758 - 762. [Abstract] [Full Text] [PDF]

				A Shulkes and J S Wilson Somatostatin in gastroenterology BMJ, May 28, 1994; 308(6941): 1381 - 1382. [Full Text]